Dimensional Fund Advisors LP Boosts Holdings in Shattuck Labs, Inc. $STTK

Dimensional Fund Advisors LP boosted its holdings in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 571.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 155,642 shares of the company’s stock after purchasing an additional 132,450 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Shattuck Labs were worth $1,001,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in shares of Shattuck Labs in the third quarter valued at approximately $38,000. Squarepoint Ops LLC acquired a new position in Shattuck Labs in the third quarter valued at about $46,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Shattuck Labs in the fourth quarter valued at $97,000. Invesco Ltd. acquired a new position in shares of Shattuck Labs in the fourth quarter valued at approximately $103,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Shattuck Labs in the fourth quarter valued at $150,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Stock Up 1.4%

NASDAQ:STTK opened at $7.42 on Friday. Shattuck Labs, Inc. has a fifty-two week low of $0.79 and a fifty-two week high of $8.33. The company has a market cap of $568.97 million, a P/E ratio of -14.55 and a beta of 1.08. The firm’s 50 day moving average is $6.43 and its two-hundred day moving average is $5.95.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Research analysts forecast that Shattuck Labs, Inc. will post -0.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Shattuck Labs

In other news, insider Arundathy N. Pandite sold 30,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total transaction of $210,300.00. Following the transaction, the insider directly owned 136,219 shares of the company’s stock, valued at approximately $954,895.19. The trade was a 18.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Abhinav A. Shukla sold 23,365 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the transaction, the insider owned 86,380 shares in the company, valued at $611,570.40. This represents a 21.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 53,875 shares of company stock valued at $379,305 over the last three months. 8.79% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on STTK shares. Leerink Partners assumed coverage on shares of Shattuck Labs in a research note on Monday, July 20th. They issued an “outperform” rating and a $16.00 price target for the company. HC Wainwright dropped their price target on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday. Wall Street Zen lowered shares of Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC upped their price target on Shattuck Labs from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Finally, Cantor Fitzgerald started coverage on shares of Shattuck Labs in a report on Monday, April 27th. They set an “overweight” rating for the company. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.12.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.